TABLE 3. Multivariate Cox Proportional Hazards Model.

Variable	Outcome	Hazards Ratio	95% CI	P
PSA >100 ng/mL	PSA failure	1.05	0.69-1.60	.181
	Metastases	0.97	0.49-1.90	.918
	Cancer survival	0.87	0.37-2.06	.749
Gleason score	PSA failure	1.14	0.97-1.33	.111
	Metastases	1.04	0.79-1.38	.763
	Cancer survival	1.28	0.90-1.83	.168
Organ confined	PSA failure	0.58	0.31-1.08	.085
	Metastases	0.32	0.06-1.75	.192
	Cancer survival	0.79	0.07-9.43	.854
Seminal vesicle invasion	PSA failure	1.25	0.77-2.03	.368
	Metastases	2.27	0.88-5.82	.089
	Cancer survival	3.26	0.76-14.07	.113
Positive margins	PSA failure	1.04	0.68-1.59	.856
	Metastases	1.09	0.51-2.31	.833
	Cancer survival	2.57	0.73-9.02	.141
Positive lymph nodes	PSA failure	1.06	0.64-1.78	.812
	Metastases	1.37	0.62-3.05	.440
	Cancer survival	3.20	1.06-9.62	.039
Adjuvant ADT	PSA failure	0.24	0.14-0.40	<.001
	Metastases	0.60	0.25-1.42	.243
	Cancer survival	0.62	0.16-2.32	.473
Adjuvant EBRT	PSA failure	0.41	0.23-0.72	.002
	Metastases	0.55	0.22-1.35	.190
	Cancer survival	0.61	0.22-1.73	.345

95% CI indicates 95% confidence interval; PSA, prostate-specific antigen; ADT, androgen deprivation therapy; EBRT, external beam radiotherapy.